You Are Here:
This topic page summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on medications for risk reduction of primary breast cancer in women.
Release Date: September 2013
- The USPSTF recommends that clinicians engage in shared, informed decisionmaking with women who are at increased risk for breast cancer about medications to reduce their risk. For women who are at increased risk for breast cancer and at low risk for adverse medication effects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen or raloxifene.
Grade: B Recommendation.
- The USPSTF recommends against the routine use of medications, such as tamoxifen or raloxifene, for risk reduction of primary breast cancer in women who are not at increased risk for breast cancer.
Grade: D Recommendation.
|Supporting Document||Related Items|
|Recommendation Statement (PDF File, 294 KB; PDF Help)||Clinical Summary (PDF File, 65 KB; PDF Help)|
|Consumer Fact Sheet (PDF File, 123 KB; PDF Help)|
|Evidence Report (PDF File, 225 KB; PDF Help)||Comparative Effectiveness Review (PDF File, 4.5 MB; PDF Help)|
Current as of October 2013
Medications for Risk Reduction of Primary Breast Cancer in Women, Topic Page. U.S. Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrpv.htm